New obesity drug HRS-5817 enters first human safety trial
NCT ID NCT06934408
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new injectable drug called HRS-5817 in healthy adults, some with obesity and some without. The main goal is to check safety and how the body handles the drug, not weight loss. About 92 volunteers will receive either the drug or a placebo to gather initial data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-5817 injection
- What this could lead to
- If successful, this could lead to a new injectable medication for weight management in people with obesity or overweight.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not weight loss. The drug may cause side effects or fail to show benefit in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Hospital of Anhui Medical Uniersity
RECRUITINGHefei, Anhui, 230601, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?